Skip to main content
Frontiers in Oncology logoLink to Frontiers in Oncology
. 2023 Jan 4;12:1124071. doi: 10.3389/fonc.2022.1124071

Erratum: Patient-specific assays based on whole-genome sequencing data to measure residual disease in children with acute lymphoblastic leukemia: A proof of concept study

Frontiers Production Office1,*
PMCID: PMC9846839  PMID: 36686724

Due to a production error, there was a mistake in Figure 6 as published. The part labels in the figure were not placed correctly. The corrected Figure 6 appears below. The publisher apologizes for this mistake.

Figure 6.

Figure 6

(A–D) Kinetics of leukemic targets in CSF and plasma by ddPCR during treatment. (A) CSF and (B) plasma results in patient 3. (C) CSF and (D) plasma results in patient 4. Empty symbols denote trace values (1–2 positive droplets). CSF, cerebrospinal fluid; ddPCR, droplet digital PCR.

The original version of this article has been updated.


Articles from Frontiers in Oncology are provided here courtesy of Frontiers Media SA

RESOURCES